Trade Ideas
Actionable trade ideas with entry/stop/target and risk framing.
Mizuho Financial (MFG) - Buy the ADR Around an India M&A Upside and Better Capital Returns
Actionable trade: buy on pullbacks as an India transaction and clearer buyback/dividend math re-rate the ADR
Mizuho Financial (ADR ticker MFG) is my preferred way to play a potential near-term rerate tied to an India M&A opportunity and management's shift tow...
Lifecore Biomedical: Early Signs of a Real Turnaround — Buy the Setup (LFCR)
CDMO contract wins, shrinking operating drag and improved cash flows create an asymmetric risk/reward ahead of 2026 catalysts
Lifecore (LFCR) looks like a classic small-cap CDMO turnaround: meaningful contract wins (10-year commercial deal + new multinational MSA), recent qua...
Xencor: Strong Balance Sheet Makes XmAb819 / XmAb942 a Lower-Risk Biotech Bet
Buy XNCR into strength — use a staged entry, tight stop, and defined targets around upcoming clinical and commercial catalysts.
Xencor (XNCR) is a clinical-stage antibody company with a diversified XmAb pipeline and an unusually robust balance sheet for a biotech at its stage. ...
Vanda into 2026: Binary Catalysts Price in a Big Move - Bysanti PDUFA + Nereus Launch
Balance sheet strength meets binary regulatory risk - actionable long with clearly defined entry, stops and targets.
Vanda (VNDA) enters 2026 with two high-impact events on deck: a potential FDA approval (PDUFA) for Bysanti and the commercial launch of Nereus. The ma...
Philip Morris: High Cash Flow and a Solid Payout, but Regulatory Bans Could Derail Growth
Buy for yield and stable cash returns, but keep a tight stop—nicotine bans remain the biggest single downside.
Philip Morris International offers a reliable dividend (annualized ~$5.88/sh) and strong operating cash flow, but regulatory risk around heated-tobacc...
Sysco: Modest Yield, Big Balance- Sheet - A Small Value Opportunity with Tight Risk Controls
SYY looks reasonably priced on an EPS multiple but balance-sheet leverage and weak near-term cash conversion limit the margin for error - a small, disciplined long for value buyers.
Sysco (SYY) is the US foodservice distribution incumbent with a visible, defensive revenue stream and a growing quarterly dividend. Recent results sho...
PagSeguro (PAGS): Buy the Yield and Durable Growth - Entry 9.2–9.9, Stop 8.0, Targets 12.5 / 15.0
Brazil-focused fintech offering double-digit growth optionality with a near 5% cash yield — tactical long for a 6–12 month position.
PagSeguro combines a sticky SME payments franchise with an expanding digital-account ecosystem. The stock trades around $9.64 with an annualized cash ...
Rigel Pharmaceuticals: Building a 2026 Playbook — Buy on Discipline, Size for Volatility
Revenue inflection, cash strength, and a clearer commercial path make RIGL a tactical long — trade plan included.
Rigel (RIGL) has moved from a cash-burning developer to a profitable, cash-rich company in 2025 thanks to accelerating revenues and expanding gross ma...
TMC: A High-Risk Long on a Potential U.S.-Backed Critical‑Mineral Story
Small position, event-driven trade: buy the policy/permit optionality — manage the balance-sheet and permitting risks tightly.
TMC the metals Co. is a pre-revenue deep-sea nodules explorer with a highly volatile share price and a narrative increasingly tied to U.S. critical‑...
Merck: Cheap, Cash-Generating Pharma Franchise — A Tactical Long with Clear Entries and Stops
Operational cash flow, steady dividends and a deep pipeline cushion a post-Keytruda transition; valuation looks stretched to the downside.
Merck is trading at a low multiple by the simple math of recent quarter results annualized. The company produced $17.3B in revenue and $5.79B in net i...
Why Viking Could Be a Speculative Play on the Oral GLP-1 Frenzy
Cash-rich balance sheet + heavy R&D = takeover optionality in a market that prizes oral metabolic assets
Viking Therapeutics (VKTX) is a paradox: no revenues, heavy R&D (Q3 2025 R&D $89.95M), and a balance sheet with large current assets ($738.7M). The ma...
Merck: Cheap Cash Flow, Growing Margin Momentum - A Tactical Long
Entry at 103-107, stop near 96, targets 120 / 140 — play the cash-flow-backed recovery while key oncology and vaccine franchises hold
Merck is reporting improving profitability and strong operating cash flow while trading at a relatively low multiple when you annualize the most recen...